Loading...
We have set up our new Discord server! Share your feedback and find like-minded people! Join our Discord
- Ticker
- HNSA.ST
- Price
- 21.88
- Stock movement down
- -0.24 (-1.08%)
- Company name
- Hansa Biopharma AB
- Exchange
- (ST ,
- Currency
- SEK )
- Sector
- Healthcare >Biotechnology
- Market cap
- 1.44B
- Ent value
- 2.14B
- Price/Sales
- 7.58
- Price/Book
- -
- Div yield
- -
- Div growth
- -
- Growth years
- -
- FCF payout
- -
- Trailing P/E
- -
- Forward P/E
- -
- PEG
- -
- EPS growth
- 20.60%
- 1 year return
- -26.68%
- 3 year return
- -28.56%
- 5 year return
- -26.49%
- 10 year return
- -4.14%
Last updated: 2025-04-12
DIVIDENDS
HNSA.ST does not pay dividends or no data was received
VALUATION
Valuation Ratios
Loading...
Valuation Ratios data
| Trailing P/E | - |
| Price to OCF | - |
| Price to FCF | - |
| Price to EBITDA | - |
| EV to EBITDA | - |
Valuation (Sales/Book Value)
Loading...
Valuation (Sales/Book Value) data
| Price to Sales | 7.58 |
| Price to Book | - |
| EV to Sales | 11.31 |
FINANCIALS
Per share
Loading...
Per share data
| Current share count | 65.61M |
| EPS (TTM) | -9.66 |
| FCF per share (TTM) | -10.33 |
Income statement
Loading...
Income statement data
| Revenue (TTM) | 189.39M |
| Gross profit (TTM) | 101.20M |
| Operating income (TTM) | -633.46M |
| Net income (TTM) | -654.78M |
| EPS (TTM) | -9.66 |
| EPS (1y forward) | -7.37 |
Margins
Loading...
Margins data
| Gross margin (TTM) | 53.43% |
| Operating margin (TTM) | -334.47% |
| Profit margin (TTM) | -345.73% |
Balance Sheet
Loading...
Please create a free account or log in to access this chart
Balance Sheet data
| Cash | 553.54M |
| Net receivables | 190.14M |
| Total current assets | 745.66M |
| Goodwill | 0.00 |
| Intangible assets | 174.84M |
| Property, plant and equipment | 20.18M |
| Total assets | 940.67M |
| Accounts payable | 51.62M |
| Short/Current long term debt | 959.19M |
| Total current liabilities | 304.19M |
| Total liabilities | 1.26B |
| Shareholder's equity | -319.96M |
| Net tangible assets | 0.00 |
Cash flow
Loading...
Please create a free account or log in to access this chart
Cash flow data
| Operating cash flow (TTM) | -700.03M |
| Capital expenditures (TTM) | 521.00K |
| Free cash flow (TTM) | -700.55M |
| Dividends paid (TTM) | 0.00 |
Financial returns
Loading...
Please create a free account or log in to access this chart
Financial returns data
| Return on Equity | - |
| Return on Assets | -69.61% |
| Return on Invested Capital | -103.83% |
| Cash Return on Invested Capital | -111.09% |
STOCK INFORMATION
Stock chart
Loading...
Stock price data
| Open | 22.18 |
| Daily high | 22.26 |
| Daily low | 20.88 |
| Daily Volume | 138K |
| All-time high | 348.00 |
| 1y analyst estimate | 100.50 |
| Beta | 1.46 |
| EPS (TTM) | -9.66 |
| Dividend per share | - |
| Ex-div date | - |
| Next earnings date | 17 Apr 2025 |
Downside potential
Loading...
Downside potential data
| HNSA.ST | S&P500 | |
| Current price drop from All-time high | -93.71% | -12.89% |
| Highest price drop | -93.97% | -56.47% |
| Date of highest drop | 13 Oct 2023 | 9 Mar 2009 |
| Avg drop from high | -46.80% | -11.07% |
| Avg time to new high | 58 days | 12 days |
| Max time to new high | 1643 days | 1805 days |
COMPANY DETAILS
Marketcap
1.44B
Marketcap category
Small-cap
Description
Hansa Biopharma AB (publ), a biopharmaceutical company, engages in development and commercialization of treatments for patients with rare immunological conditions in Europe and the United States. The company offers Idefirix(imlifidase), which targets and cleaves all classes of immunoglobulin G (IgG) antibodies for the desensitization treatment of sensitized adult kidney transplant patients with a positive crossmatch test. It is also developing Novel immunoglobulin cleaving enzymes for Repeat dosing (NiceR) for the treatment of autoimmune diseases, transplantation, and oncology; and Enzyme based antibody Enhancement (EnzE), which is cancer immunotherapy. The company has a collaboration agreement with Sarepta Therapeutics to assess imlifidase as a pre-treatment in limb-girdle muscular dystrophy (LGMD) and duchenne muscular dystrophy (DMD); AskBio to evaluate imlifidase as a pre-treatment in pompe disease; and research and development collaboration agreement with Genethon to evaluate the safety and efficacy of imlifidase as pre-treatment to gene therapy in Crigler-Najjar syndrome patients with anti-AAV antibodies. Hansa Biopharma AB (publ) was incorporated in 2007 and is headquartered in Lund, Sweden.
Employees
135
Investor relations
-
SEC filings
CEO
Country
Sweden
City
Stock type
-
CCC status
-
Dividend Frequency
-
EVENTS AND PRESENTATIONS
EventsPresentations
Loading...
UNDERSTAND THE BUSINESS
Loading...
COMPANY NEWS
All newsPress releases
Hansa Biopharma AB, 'Hansa' (Nasdaq Stockholm: HNSA), announced today that it has completed enrolment of its 20-HMedIdeS-19 Post Authorization Efficacy and Safety (PAES) study, an open-label Phase 3 c...
March 11, 2025
Hansa Biopharma AB, Hansa or the Company (Nasdaq Stockholm: HNSA) today announced its full year and Q4 2024 financial results.
February 6, 2025
Hansa Biopharma AB, "Hansa" or the "Company" (Nasdaq Stockholm: HNSA), today announced that management will attend the 43rd Annual J.P. Morgan Healthcare Conference. If you are interested in a meeting...
January 7, 2025
Hansa Biopharma, "Hansa" (Nasdaq Stockholm: HNSA), today announced positive full results from the 15-HMedIdeS-09 single arm Phase 2 study of imlifidase, a first in class IgG cleaving enzyme, in Guilla...
December 17, 2024
Hansa Biopharma, "Hansa" (Nasdaq Stockholm: HNSA) today announced it has completed the enrolment of patients in the GOOD-IDES-02 trial, a global pivotal Phase 3 trial in anti-glomerular basement membr...
December 5, 2024
LUND, Sweden & EVRY, France, December 03, 2024--This is a crucial step in order to make gene therapy more effective and to increase the number of patients able to access it.
December 3, 2024
Hansa Biopharma, "Hansa" (Nasdaq Stockholm: HNSA) today announced it will attend Truist Securities BioPharma Symposium on November 7 in New York, NY. Hitto Kaufmann, Chief R&D Officer at the Company w...
October 30, 2024
Hansa Biopharma today announced its interim report for January-September and third quarter 2024 financial results.
October 17, 2024
Hansa Biopharma AB, ("Hansa" or the "Company") (NASDAQ STOCKHOLM: HNSA), today announced positive results from a 12-month follow up analysis from the NICE-01 trial of HNSA-5487, the Company's next gen...
October 7, 2024
Hansa Biopharma today announced that Søren Tulstrup will participate in a Fireside chat hosted by Douglas Tsao, Managing Director and Senior Financial Analyst at H.C. Wainwright on Wednesday, Septembe...
September 5, 2024
Next page